Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity
Sebastian Ols,
Lifei Yang,
Elizabeth A. Thompson,
Pradeepa Pushparaj,
Karen Tran,
Frank Liang,
Ang Lin,
Bengt Eriksson,
Gunilla B. Karlsson Hedestam,
Richard T. Wyatt,
Karin Loré
Affiliations
Sebastian Ols
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, 171 64 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
Lifei Yang
IAVI Neutralizing Antibody Center, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
Elizabeth A. Thompson
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, 171 64 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
Pradeepa Pushparaj
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
Karen Tran
IAVI Neutralizing Antibody Center, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
Frank Liang
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, 171 64 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
Ang Lin
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, 171 64 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
Bengt Eriksson
Astrid Fagraeus Laboratory, Comparative Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
Gunilla B. Karlsson Hedestam
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
Richard T. Wyatt
IAVI Neutralizing Antibody Center, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
Karin Loré
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, 171 64 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden; Corresponding author
Summary: Although intramuscular (i.m.) administration is the most commonly used route for licensed vaccines, subcutaneous (s.c.) delivery is being explored for several new vaccines under development. Here, we use rhesus macaques, physiologically relevant to humans, to identify the anatomical compartments and early immune processes engaged in the response to immunization via the two routes. Administration of fluorescently labeled HIV-1 envelope glycoprotein trimers displayed on liposomes enables visualization of targeted cells and tissues. Both s.c. and i.m. routes induce efficient immune cell infiltration, activation, and antigen uptake, functions that are tightly restricted to the skin and muscle, respectively. Antigen is also transported to different lymph nodes depending on route. However, these early differences do not translate into significant differences in the magnitude or quality of antigen-specific cellular and humoral responses over time. Thus, although some distinct immunological differences are noted, the choice of route may instead be motivated by clinical practicality. : Route of immunization, especially intramuscular versus subcutaneous administration, is often debated. Ols et al. use a rhesus macaque model to determine the tissues targeted by a nanoparticle vaccine administered by either route. The authors demonstrate that tissue dissemination is route dependent, but innate and adaptive immune responses develop comparably. Keywords: vaccination, intramuscular, subcutaneous, antigen transport, HIV envelope glycoprotein, dendritic cell, follicular dendritic cell, monocytes, lymph node, B cell follicle